Lexaria Bioscience Corp.
LEXX
Positions held
Your positionsLEXX isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $6.74M | Enterprise value | $1.36M | Trailing P/E | — | Forward P/E | -8.21 |
| PEG | — | Price / book | 1.12 | Beta | 0.60 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 100.0% | Operating margin | -38.6% |
| Profit margin | 0.0% | ROE | -1.6% | ROA | -81.3% | Debt / equity | 0.02 |
| Current ratio | 10.60 | Free cash flow | -$4.69M | Analyst recommendation | none | Mean target | $82.50 |
| 52w high | $21.60 | 52w low | $2.77 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.2M | $0.2M | — |
| Op margin | — | -7259.5% | — | -1545.2% | -2155.4% | — |
| Net income | -$2.0M | -$1.4M | -$1.6M | -$2.7M | -$3.8M | — |
| Gross margin | — | 100.0% | — | 100.0% | 100.0% | — |
| Gross profit | $0.0M | $0.0M | $0.0M | $0.2M | $0.2M | — |
| Operating income | -$2.0M | -$1.5M | -$1.6M | -$2.7M | -$3.8M | — |
- Revenue -100% vs prior quarter ($0 vs $0.0M).
- Gross margin 100% (was 100% prior quarter).
- Operating margin compressed to -7259.5%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.7M | $0.5M | $0.2M | $0.3M |
| Op margin | -1683.0% | -1239.2% | -2888.5% | -2591.7% |
| Net income | -$11.9M | -$5.8M | -$6.7M | -$7.3M |
| Gross margin | 99.6% | 99.0% | 86.1% | 71.9% |
| Gross profit | $0.7M | $0.5M | $0.2M | $0.2M |
| Operating income | -$11.9M | -$5.8M | -$6.5M | -$6.6M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-06 · GLP-1 Weight-Loss/Diabetes Industries Continue Transition to Oral Medications
2026-09-17 · Lexaria Updates Financial Position
2026-09-09 · Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds
2026-09-08 · Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds
2026-09-08 · LEXX: Introducing DehydraTECH 3.0
2026-09-04 · Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-01 · Lexaria Receives USD$2.6 Million Tax Rebate Payment
2026-08-13 · Lexaria Enters a Material Transfer Agreement With PegBio
2026-07-30 · Lexaria Announces Effective Date for Reverse Stock Split
2026-07-17 · LEXX: Dosing Started for Animal & Human GLP-1 Studies
Price (daily)
Full chart · RSI · MACD · patterns